- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07848373
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This 1 month 3 visit, single arm open label study aims to determine if acoltremon 0.003% can improve the frequency and severity of Dry Eye Disease (DED) symptoms in CL wearers. DED is a multifactorial condition that can cause stinging, burning sensation or dry eyes. It can also have clinically significant findings such as decreased tear production (aqueous-deficient DED) or increased tear evaporation (evaporative DED). Conditions like this often lead to discomfort, and thus individuals to drop out of wearing contact lenses. With nearly 20% of CL dropouts annually being due to discomfort.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
- Navn: Chris Lievens, OD, PhD
- Telefonnummer: 901-481-5699
- E-mail: clievens@sco.edu
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
• Adult subjects who are ≥18 years of age.
- Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25).
- Willing to wear a new pair of CLs to the baseline study visit.
- Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).
- An Eye Dryness VAS score of ≥40.
- CLDEQ-8 scores (CLDEQ-8 scores ≥12).
- A score of >7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).
- Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.
- Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.
- Habitual CLs have an acceptable fit (good centration, movement, and coverage
Exclusion Criteria:
- Any history of acoltremon 0.003% use.
- Are currently an overnight CL wearer.
- Are currently hard or scleral CL wearers.
- Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).
- Have a history of ocular surgery within the past 12 months.
- Have a history of viral eye disease that may confound study results.
- Have a history of severe ocular trauma, active ocular infection or inflammation.
- Have ever used isotretinoin-derivates (e.g., Accutane).
- Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.
- Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).
- Have used a prescription DED medication in the last 1 month.
- Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.
- Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.
- Are pregnant or breast feeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: acoltremon 0.003%
participants will be provided with acoltremon 0.003% and instructed to use it twice a day. |
Acoltremon 0.003% (TRYPTYR; Alcon Laboratories; Fort Worth, TX, USA) was recently approved by the US Food and Drug Administration (FDA) as the first transient receptor potential melastatin (TRPM8) agonist for the treatment of DED. Acoltremon 0.003% is dosed twice a day |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Eye Dryness Score (VAS) at 4 weeks compared to baseline
Tidsramme: 1 month
|
participants will be asked to evaluate their eye dryness using a VAS scale with higher numbers indicating greater comfort. |
1 month
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Eye Dryness Score (VAS) at 2 weeks compared to baseline
Tidsramme: two weeks
|
participants will be asked to complete an eye dryness visual analog scale with higher numbers indicating greater comfort |
two weeks
|
|
CL End of day comfort VAS
Tidsramme: 4 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
4 weeks
|
|
CL End of day comfort VAS
Tidsramme: 2 weeks
|
participants will be asked to complete a contact lens comfort visual analog scale with higher numbers indicating greater comfort |
2 weeks
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Tidsramme: 1 month
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
1 month
|
|
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
Tidsramme: 2 weeks
|
participants will be asked to complete the CLDEQ-8 questionnaire with lower scores indicating more comfort |
2 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB000673-Acoltremon dry eye
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
An abstract describing the primary outcome will be submitted for ARVO 2027, and a manuscript on the same topic will be submitted to Contact Lens & Anterior Eye or similar publication. An abstract related to the Likert survey results will be submitted to Optometry's Meeting 2027
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .